Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line.

NCT03413579 is registered in ClinicalTrials.gov with El Kendi Pharmaceuticals Manufacturing Company as lead sponsor.

NCT NCT03413579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03413579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line.
Lead sponsor
El Kendi Pharmaceuticals Manufacturing Company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
February 28, 2021
Enrollment
37 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer